Overview


According to FutureWise analysis the market for vagus nerve stimulation in 2023 is US$ 0.48 billion, and is expected to reach US$ 1.08 billion by 2031 at a CAGR of 10.80%.

Vagus nerve is a crucial part of the autonomic nervous systems that controls involuntary body functions like heart rate. It passes from the abdomen to the lower part of the brain via chest and neck. Vagus nerve stimulation therapy is developed to prevent seizures by consistently sending mild electrical pulses through the vagus nerve to the brain. The VNS device is referred as the ‘brain pacemaker’ and it is placed on the chest wall under the skin. The vagus nerve is connected to the device using a wire. Vagus nerve stimulators are used for curing treatment resistant depression and intractable epilepsy.

The rising incidences of neurological disorders like epilepsy, obtaining efficient clinical outcomes using this technique are some crucial factors contributing to the vagus nerve stimulation market growth. Conversely, a lack of skilled healthcare professionals and step costs related with these devices shall restrain the market growth. On the other hand, rising research and development activities for expanding the range of applications of using neurostimulators shall provide substantial growth opportunities to the market.

  • Medtronic Plc.
  • ElectroCore LLC
  • LivaNova Plc.
  • Boston Scientific Corporation
  • Aleva Neurotherapeutics SA
  • BioControl Medical
  • Bioness Inc.
  • EnteroMedics Inc.
  • Nevro Corporation
  • NeuroPace Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Implantable VNS Devices
  • External VNS Devices

By Application

  • Depression
  • Epilepsy
  • Migraine

By Biomaterial

  • Ceramics
  • Metallic
  • Polymerics

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The market is classified into product, application, biomaterial, end user and region. The product segment is fragmented into implantable VNS devices and external VNS devices. The external VNS devices are predicted to hold the largest vagus nerve stimulation market share as the process of fitting this device is minimally invasive, which is highly preferred by patients and is also a cheaper alternative than an implantable VNS device. The application segment is categorised into depression, epilepsy and migraine. The depression segment is predicted to lead the market as VNS devices are primarily used for treating treatment resistant depression. The biomaterial segment is divided into ceramic, metallic and polymerics. The end user segment is categorised into hospitals, ambulatory surgical centres and others. The hospital segment is anticipated to dominate the market owing to advancements in the hospital infrastructure, rise in the number of multispecialty hospitals and rising patient population across the world.

The North America region is predicted to dominate the market owing to a strong presence of key market players in the region. Furthermore, unprecedented advancements in the healthcare infrastructure in the region shall boost its market growth. Additionally, there has been a rising awareness amongst patients regarding neurological disorders and alternatives to treat them.

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Global Vagus Nerve Stimulation Market By Product, By Application, By Biomaterial, By End User and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Vagus Nerve Stimulations Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework on Country Level
         6.1 . Reimbursement Framework
         6.2 . Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1 . Market Driver Analysis
         1.2 . Market Restraint Analysis
         1.3 . Industry Challenges
  • 6.   Vagus Nerve Stimulations Market Analysis tools
    •   1. Industry Analysis - Porter’s
         1.1 . Supplier Power
         1.2 . Buyer Power
         1.3 . Substitution Threat
         1.4 . Threat from new entrants
         1.5 . Competitive Rivalry
        2. Pestel Analysis
         2.1 . Political Landscape
         2.2 . Environmental Landscape
         2.3 . Social landscape
         2.4 . Technology landscape
         2.5 . Legal Landscape
  • 7.   Vagus Nerve Stimulations Market, By Product Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Implantable VNS Devices
        2. External VNS Devices

  • 8.   Vagus Nerve Stimulations Market, By Application Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Depression
        2. Epilepsy
        3. Migraine

  • 9.   Vagus Nerve Stimulations Market, By Biomaterial Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Ceramics
        2. Metallic
        3. Polymerics

  • 10.   Vagus Nerve Stimulations Market, By End User Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Hospitals
        2. Ambulatory Surgical Centers
        3. Others

  • 11.   North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1. U.S.
         2.2. Canada
         2.3. Mexico
         2.4. Rest of North America
        3. Market Size (USD Mn) Forecast for North America 2023-2031

  • 12.   Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
         3.1. Brazil
         3.2. Venezuela
         3.3. Argentina
         3.4. Rest of Latin America
        4. Market Size (US$ Mn) Forecast for Latin America 2023-2031

  • 13.   Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5 . Switzerland
         2.6. Spain
         2.7. Russia
         2.8. Poland
         2.9. Rest of Western Europe
        3. Market Size (US$ Mn) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. Korea
         2.5. India
         2.6. Australia and New Zealand
         2.7. ASEAN
         2.8. Rest of Asia Pacific
        3. Market Size (US$ Mn) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (US$ Mn) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. Medtronic Plc.
         1.1. Company Overview (HQ, Business Segments, Employee Strength)
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. ElectroCore LLC
         2.1. Company Overview (HQ, Business Segments, Employee Strength)
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. LivaNova Plc.
         3.1. Company Overview (HQ, Business Segments, Employee Strength)
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Boston Scientific Corporation
         4.1. Company Overview (HQ, Business Segments, Employee Strength)
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Aleva Neurotherapeutics SA
         5.1. Company Overview (HQ, Business Segments, Employee Strength)
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. BioControl Medical
         6.1. Company Overview (HQ, Business Segments, Employee Strength)
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bioness Inc.
         7.1. Company Overview (HQ, Business Segments, Employee Strength)
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. EnteroMedics Inc.
         8.1. Company Overview (HQ, Business Segments, Employee Strength)
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Nevro Corporation
         9.1. Company Overview (HQ, Business Segments, Employee Strength)
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. NeuroPace Inc.
         10.1. Company Overview (HQ, Business Segments, Employee Strength)
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients